PsA: Clinical and therapeutic features associated with early vs late onset of psoriasisJuly 31, 2022Psoriatic Arthritis
Reluctance of biologic initiation in systemic-therapy-naive PsA patients receiving apremilastJuly 31, 2022Psoriatic Arthritis
PsA: Long-term retention, efficacy, and safety of secukinumab in real worldJuly 31, 2022Psoriatic Arthritis
Guselkumab leads to meaningful and consistent improvement in general health outcomes in PsAJuly 31, 2022Psoriatic Arthritis
PsA: Risankizumab improves patient-reported outcomes in phase 3 trialJuly 31, 2022Psoriatic Arthritis
PsA: Sustained improvement in patient-reported outcomes with bimekizumabJuly 31, 2022Psoriatic Arthritis
PsA: Long-term efficacy and safety of ixekizumab with or without csDMARDJuly 31, 2022Psoriatic Arthritis
Rapid and sustained improvement in diverse PsA manifestations with guselkumabJuly 31, 2022Psoriatic Arthritis
Real-world data on efficacy of abatacept vs TNFi in ACPA-positive RAJuly 31, 2022Rheumatoid Arthritis
Discontinuing bDMARD or tofacitinib appears viable in RA patients achieving stable disease control July 31, 2022Rheumatoid Arthritis
Prior bariatric surgery associated with better in-hospital outcomes in patients with RAJuly 31, 2022Rheumatoid Arthritis
Sarcopenia and poor balance increase risk for vertebral spinal osteoporotic fracture in women with RAJuly 31, 2022Rheumatoid Arthritis
RA: Rapid improvements in patient-reported outcomes with upadacitinib vs abataceptJuly 31, 2022Rheumatoid Arthritis
RA: Ozoralizumab shows promise in patients with inadequate response to methotrexateJuly 31, 2022Rheumatoid Arthritis
